Published online May 14, 2019. doi: 10.3748/wjg.v25.i18.2188
Peer-review started: September 29, 2018
First decision: November 7, 2018
Revised: March 21, 2019
Accepted: March 29, 2019
Article in press: March 30, 2019
Published online: May 14, 2019
Core tip: The efficacy of lyophilized probiotic yeast Saccharomyces boulardii CNCM I-745 was clinically demonstrated with controlled studies of intestinal infections associated with antibiotics and acute diarrhea in children. This review summerizes scientific data describing the mechanism of Saccharomyces boulardii protection against infection and emphazises the diversity of potential mechanism of action that this probiotic yeast can have against pathogenic microorganisms. More recently, effects on the recovery of the intestinal microbiota as well as on the immune system have been demonstrated, thus opening up a new therapeutic potential of this yeast.